Drug/Small Molecule:
mebendazole

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
Trade Names
  • Bantenol
  • Besantin
  • Equivurm Plus
  • Lomper
  • MBDZ
  • MEBENDAZOLE, 99%
  • Mebendazole (JAN/USP)
  • Mebendazole(USAN)
  • Mebenoazole
  • Mebenvet
  • Mebex
  • Mebutar
  • Noverme
  • Ovitelmin
  • Pantelmin
  • Telmin
  • Vermicidin
  • Vermirax
  • Vermox
  • Vermox (TN)
  • Verpanyl
Brand Mixture Names
  • Bot-Plus Syringe Formula Equine Wormer (Mebendazole + Trichlorfon)
  • Equiverm B Pst (Mebendazole + Trichlorfon)
  • Telmin B Syringe Formula (Mebendazole + Trichlorfon)

PharmGKB Accession Id:
PA164776669

Description

A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules.

Source: Drug Bank

Indication

For the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Mebendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.

Source: Drug Bank

Pharmacology

Mebendazole is a (synthetic) broad-spectrum anthelmintic. The principal mode of action for Mebendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.

Source: Drug Bank

Food Interaction

Lipid rich meals may improve absorption.|Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Primarily hepatic. Primary metabolite is 2-amino-5-benzoylbenzimidazole, but also metabolized to inactive hydroxy and hydroxyamino metabolites. All metabolites are devoid of anthelmintic activity.

Source: Drug Bank

Protein Binding

90-95%

Source: Drug Bank

Absorption

Poorly absorbed (approximately 5 to 10%) from gastrointestinal tract. Fatty food increases absorption.

Source: Drug Bank

Half-Life

2.5 to 5.5 hours (range 2.5 to 9 hours) in patients with normal hepatic function. Approximately 35 hours in patients with impaired hepatic function (cholestasis).

Source: Drug Bank

Toxicity

Acute oral toxicity (LD 50): 620 mg/kg Mouse. Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.

Source: Drug Bank

Route of Elimination

In man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.

Source: Drug Bank

Chemical Properties

Chemical Formula

C16H13N3O3

Source: Drug Bank

Isomeric SMILES

COC(=O)Nc1[nH]c2ccc(cc2n1)C(=O)c3ccccc3

Source: OpenEye

Canonical SMILES

COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

295.2927

Source: Drug Bank

Monoisotopic Molecular Weight

295.095691297

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
TUBA1A (source: Drug Bank)
TUBB4B (source: Drug Bank)

Drug Interactions

Drug Description
mebendazole The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)
ethotoin The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)
fosphenytoin The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)
mephenytoin The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)
phenytoin The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)
mebendazole The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)
mebendazole The hydantoin decreases the efficiency of mebendazole (source: Drug Bank)

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0093-9107-29
DrugBank:
DB00643
ChEBI:
6704
KEGG Drug:
D00368
PubChem Compound:
4030
PubChem Substance:
46508807
7847434
Drugs Product Database (DPD):
556734
ChemSpider:
3890
Therapeutic Targets Database:
DAP000950
FDA Drug Label at DailyMed:
107c3ad5-6ebe-4c98-a4a8-ac36663bd6a7

Clinical Trials

These are trials that mention mebendazole and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.